HA-CD44 targeted nanoparticles are being investigated against this subtype of breast cancer [22,23,24] as it is not responsive to other common receptors and effective current treatments, though generalizing results to other subtypes remains logical and CD44 is expressed in various subtypes of breast cancer that are drug resistant. This evidence concerns the gene CD44 and breast cancer.